Pharmos Corporation recently announced the completion of its first round of testing of a topical cream used as a drug delivery device for an anti-inflammatory drug. Pharmos stated the test data indicated there were no “severe or serious adverse events” and that the “formulation was safe and well tolerated” in human test subjects. Pharmos applauded the “skin penetrative properties” of the nano-forumlation, and pointed to successful animal studies indicating “excellent targeted delivery” through this method.
PR Newswire US, November 14, 2006, “Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream; Data Indicate Positive results Achieved on Safety, Tolerability and Pharmacokinetics.”
